Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor versus placebo in advanced unresectable dedifferentiated liposarcoma
MOH_2020-03-17_008778Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of selinexor in dedifferentiated liposarcoma (DDL) (3 arms), sponsored by Karyopharm Therapeutics Inc. Started Apr 2018; status: completed.
02
Drugs
selinexor
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on MOH_2020-03-17_008778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-17_008778.